BioSpace News Archive

Bio-Path Holdings, Inc., a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in a public offering.

As COVID-19 activity continues in Canada, we are tracking a range of epidemiological indicators to monitor where the disease is most active, where it is spreading and how it is impacting the health of Canadians and public health, laboratory and healthcare capacity.

Data to be presented during the 2021 American Society of Clinical Oncology’s Genitourinary Cancers Symposium and simultaneously published in The Lancet

KEYTRUDA Plus LENVIMA Significantly Reduced Risk of Disease Progression or Death by 61% Versus Sunitinib, With a Median PFS of Nearly Two Years Versus Nine Months for Sunitinib

The American College of Prosthodontists welcomes Mark C. Hutten, DDS, MS, FACP, as the organization’s new president.